JFG
CBIO

Jefferies Financial Group’s Crescent Biopharma CBIO Stock Holding History

Jefferies Financial Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-64,244
Closed -$762K – 1923
2025
Q4 		$762K Sell
64,244
-38,470
-37% -$490K ﹤0.01% 1194
2025
Q3 		$1.22M Buy
102,714
+75,618
+279% +$1M 0.01% 803
2025
Q2 		$437K Buy
27,096
+21,246
+363% +$449K ﹤0.01% 938
2025
Q1 		$123K Buy
5,850
+1,612
+38% +$43.1K ﹤0.01% 1451
2024
Q4 		$106K Buy
+4,238
New +$116K ﹤0.01% 1454
2024
Q2 		– Sell
-382
Closed -$115K – 1571
2024
Q1 		$115K Buy
+382
New +$114K ﹤0.01% 1419

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jefferies Financial Group's CBIO Position: Q1 2026 in Review

Jefferies Financial Group sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 64,244 shares — an estimated $762K sold.

Jefferies Financial Group first reported a position in CBIO in Q1 2024 and held it in 6 quarters. The position peaked at $1.22M in Q3 2025. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Jefferies Financial Group reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 64,244 Crescent Biopharma shares in Q1 2026, an estimated $762K.
  • Jefferies Financial Group first reported a position in Crescent Biopharma in Q1 2024 and held it in 6 quarters.
  • Jefferies Financial Group's Crescent Biopharma position peaked at $1.22M in Q3 2025.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.